| 14 1.53 (12.27%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 16.83 |
1-year : | 19.66 |
| Resists | First : | 14.41 |
Second : | 16.83 |
| Pivot price | 12.54 |
|||
| Supports | First : | 12.52 |
Second : | 11.35 |
| MAs | MA(5) : | 12.54 |
MA(20) : | 12.75 |
| MA(100) : | 10.57 |
MA(250) : | 6.24 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55 |
D(3) : | 36.3 |
| RSI | RSI(14): 63.1 |
|||
| 52-week | High : | 14.41 | Low : | 1.53 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLYM ] has closed Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.01 - 14.11 | 14.11 - 14.19 |
| Low: | 12.27 - 12.37 | 12.37 - 12.44 |
| Close: | 13.86 - 14.03 | 14.03 - 14.15 |
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Thu, 06 Aug 2026
Climb Bio, Inc. Q2 2026: Net loss $(13.5M), EPS $(0.18) — 10-Q Summary - TradingView
Thu, 06 Aug 2026
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Thu, 06 Aug 2026
Climb Bio expects CLYM116 Phase 2 dosing to begin in Q3 - Stock Titan
Mon, 03 Aug 2026
CLIMB BIO INC : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $23 - Bitget
Mon, 03 Aug 2026
CLIMB BIO INC : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $23 - Bitget
Tue, 28 Jul 2026
Climb Bio Builds Momentum With Late-2026 Data Readouts; Wedbush Sets $20 Target - RTTNews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 64.9 (%) |
| Shares Short | 6,870 (K) |
| Shares Short P.Month | 3,000 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.3 % |
| Return on Equity (ttm) | -31 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -18.19 |
| PEG Ratio | 0 |
| Price to Book value | 4.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|